Table 2 Ongoing studies of first-line treatments for HER2 positive metastatic breast cancer
Study | Arms of Treatment | Population | N. of patients | Obiectives of Study |
|---|---|---|---|---|
Peruse (MO28047) | P + T + Tx | mBC HER 2+ | 1436 | Multicenter clinical practice, single-arm phase IV study to evaluate the safety of the combination in real life world |
Pertain (MO27775) | P + T + AI vs T + AI | mBC HER2+ HR+ Post menopausal status | 250 | Randomized multicenter open label phase II study designed to assess the efficacy and safety of P+ T + AI [anastrozole or letrozole) or T+ AI. Pts in either arm may also receive induction chemotherapy for up to 18 weeks at the investigator’s discretion. |
Velvet (MO27782) | P + T + VNR | mBC HER2+ | 210 | Randomized, multicenter open-label, single-arm with 2 cohorts of patients (cohort 1 = sequential infusion of P and T; cohort 2 concomitant P and T) designed to evaluate the efficacy and safety of P in combination with VNR |
Metapher (BO29159) | P + T (s.c) + Tx | mBC HER2+ | 400 | Multicenter single-arm phase IIIb study, designed to evaluate the safety and efficacy of the combination P + T subcutaneously + Tx |